they also need to put in a requirement that if you accept the prize money, then you give up the patent, allowing generic drugs.
Otherwise I foresee a case where they take the $2 billion profit, then go ahead and charge $10,000 a pill, just like cancer drugs.
In that situation where they cannot actually manufacture the drug in commercially viable situation, mostly likely they will never commercially manufacture the drug and there will only be generics. This will severely complicate the regulatory process as generics are generally licensed relative to their non-generic counterparts. Since there won't be any non-generics, there will little to benchmark the purity and efficacy of the generic drugs against. For some things this may not be a problem, but it seems that in general it will lead to only sub-optimal drugs being available.
I think what most people forget is that the delivery system is often as important as the active chemical in many drug treatments. Sure there are many common delivery mechanisms like pills that dissolve in the stomach and deliver the drug at certain pre-determined rate (commonly known as time-release), but many generic manufacturers attempt to move up the generic food chain by offering customized delivery systems that aren't part of the original study (e.g., time release instead of 2 doses a day, or multi-valent) or are incapable of producing the original tested delivery system (e.g., transdermal, to avoid stomach acid and intestinal absorption issues, etc) and simply produce chemically equivalent pill formulations that have off-the-shelf inactive compounding ingredients that involve little testing under the assumption of bio-equivalence or bio-availablity. Conversely, they might not be chemically equivalent (e.g., have more or less active ingredients), but in conjunction with the delivery system have similar bio-availablity (on average, but not necessarily for different individuals) or be "juiced" to counter chemical shelf life degradation (to improve profit margin on the generics).
Most likely simple broad-spectrum antibiotic drugs in generic pill form probably won't suffer many of these issues, but the issue of generics isn't as simple as most people make it out to be...
I think it's easy to argue that things should be available to the masses as soon as possible, but the initial availability is also an important part of the drug release process. Having this as standard as possible helps to make sure that the drug can be fine-tuned before it gets to the generic stage. You might also argue of the length of the initial availability period, but it's arguable that if a patent is 20 years, and it takes 10 years for approval, that 5-10 years of widespread availability in a standard form for a drug with potential short and long term side effects might not be totally unreasonable. But I guess that all depends on risk tolerance (f thousands of people are dying of a resistant bacterial infection, the relative risk of less testing might be lower)...